Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 6/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.40 |
| ▸ | MIF | P14174 | 3/20 | 0.39 |
| ▸ | CD74 | P04233 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16475230 | 1.00 | LPL (0.40) | LPLLIPGMIFCD74IDO1 | |
| SCHEMBL782308 | 0.90 | LPL (0.41) | LPLLIPGIDO1KMT2AMEN1 | |
| SCHEMBL17420933 | 0.89 | ALDH1A1 (0.46) | LPLLIPGMIFALDH1A1SMN1; SMN2 | |
| SCHEMBL26614707 | 0.86 | KMO (0.42) | MIFCD74IDO1KMT2AMEN1 | |
| SCHEMBL30639730 | 0.86 | CSF1R (0.40) | MIFCD74IDO1KMT2AMEN1 | |
| SCHEMBL30639708 | 0.86 | MIF (0.37) | LPLLIPGMIFCD74IDO1 | |
| SCHEMBL26614727 | 0.86 | MIF (0.37) | LPLLIPGMIFCD74IDO1 | |
| SCHEMBL26614779 | 0.86 | CSF1R (0.40) | MIFCD74IDO1KMT2AMEN1 | |
| SCHEMBL30639689 | 0.86 | KMO (0.42) | MIFCD74IDO1KMT2AMEN1 | |
| SCHEMBL30639740 | 0.85 | CA1 (0.36) | LPLLIPGMIFCD74IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282728-A1 | NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR | CEREVANCE INC (US) | 2025-09-11 | — | — | US | disclosed |
| EP-4514788-A1 | NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR | Cerevance, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023209368-A1 | NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR | Cerevance, Inc. (US) | 2023-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282728-A1 | NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR | GPR55, GPR68, GPR65 | LPL 2320/4885LIPG 1956/4885MIF 3999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.